Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Income from Continuing Operations: 2022-2023

Historic Income from Continuing Operations for Lexeo Therapeutics (LXEO) over the last 1 years, with Dec 2023 value amounting to -$14.2 million.

  • Lexeo Therapeutics' Income from Continuing Operations rose 2.68% to -$14.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$66.4 million, marking a year-over-year change of. This contributed to the annual value of -$98.3 million for FY2024, which is 48.11% down from last year.
  • Per Lexeo Therapeutics' latest filing, its Income from Continuing Operations stood at -$14.2 million for Q4 2023, which was up 29.45% from -$20.1 million recorded in Q3 2023.
  • In the past 5 years, Lexeo Therapeutics' Income from Continuing Operations ranged from a high of -$13.4 million in Q2 2023 and a low of -$20.1 million during Q3 2023.
  • Moreover, its 2-year median value for Income from Continuing Operations was -$15.8 million (2022), whereas its average is -$16.3 million.
  • Examining YoY changes over the last 5 years, Lexeo Therapeutics' Income from Continuing Operations showed a top increase of 2.68% in 2023 and a maximum decrease of 17.90% in 2023.
  • Over the past 2 years, Lexeo Therapeutics' Income from Continuing Operations (Quarterly) stood at -$14.6 million in 2022, then increased by 2.68% to -$14.2 million in 2023.
  • Its Income from Continuing Operations was -$14.2 million in Q4 2023, compared to -$20.1 million in Q3 2023 and -$13.4 million in Q2 2023.